Credit and interest ratespositive · 4 filings
“The Senior Credit Facility is subject to various financial and negative covenants and, at March 31, 2026, the Company was in compliance with all such covenants.”10-Q · May 5, 2026 ↗
Integra LifeSciences Holdings Corporation
IART
Market read
Integra LifeSciences Holdings Corporation's move is spreading beyond its market group.
No new filing conclusion is available. 5 of 25 group members are active now; 3 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
Company-4.3% todayVolume comparison unavailable
Market group5 of 25 activeBiopharmaceuticals and Care · inactive
Disclosed network0 of 4 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- At least 17 of 25 durable members become active together.
- Capital-flow agreement rises above 55%.
- BDX remains aligned with the group in the next market snapshot.
Invalidation: The live read weakens if participation falls to 8 of 25 members or fewer.
Research brief
The story so far
No new filing conclusion is available. 5 of 25 group members are active now; 3 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- At least 17 of 25 durable members become active together.
- Capital-flow agreement rises above 55%.
- BDX remains aligned with the group in the next market snapshot.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods9
Price observations319
Usable filing statements85
Verified relationships4
Evidence supporting the case
- Credit and interest rates has repeated favorable evidence across 4 filings.
- Supply chain and availability has repeated favorable evidence across 3 filings.
Evidence challenging the case
- Operating margin changed -31.9 percentage points in the latest annual period.
- Net margin changed -31.2 percentage points in the latest annual period.
- Foreign exchange has repeated adverse evidence across 3 filings.
Questions before a position
- EV/sales is 88% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 10, 2026
15.576m+36.8%12m+4.7%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$1.5B+12.4%$1.98+0.3%
2022-12-31$1.6B+1.0%$2.16-2.3%
2023-12-31$1.5B-1.0%$0.84-3.8%
2024-12-31$1.6B+4.5%$-0.09-4.1%
2025-12-31$1.6B+1.5%$-6.74-0.4%
What management says matters
Persistent and emerging business drivers
Legal and regulatory exposuremixed · 4 filings
“The Senior Credit Facility is subject to various financial and negative covenants and, at March 31, 2026, the Company was in compliance with all such covenants.”10-Q · May 5, 2026 ↗
Product pipeline and R&Dmixed · 4 filings
“Research and Development Research and development expenses for the three months ended March 31, 2026 decreased by $1.2 million as compared to the same period in the prior year, primarily attributable to cost management initiatives in the current year.”10-Q · May 5, 2026 ↗
Foreign exchangenegative · 3 filings
“Other (Expense) Income, Net Other (expense) income, net for the year ended December 31, 2025 decreased by $6.3 million as compared to the same period in the prior year, primarily driven by foreign exchange impact related to EUR and CHF denominated balances.”10-K · Feb 26, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 0.7× · EV/sales 1.0×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
15.57-4.3% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for IART. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for IART. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind IART
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
MDTMedtronic plcsupplierFeb 26, 2026 ▾
“Durepair® Acquisition On October 2, 2024, the Company completed the acquisition of the product rights for the Durepair ® Regeneration Matrix (“Durepair”), a non-synthetic dura substitute for repair of the dura mater during neurosurgical procedures, from Medtr…”
Depended on by
AORTArtivion, Inc.competitorFeb 18, 2026 ▾
“BioGlue competes primarily with surgical sealants from Baxter, Ethicon, Grena Ltd, Integra LifeSciences, and Bard, a subsidiary of BD.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
IART is currently a Participant in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.